<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298268</url>
  </required_header>
  <id_info>
    <org_study_id>C-CUSATR-001</org_study_id>
    <nct_id>NCT04298268</nct_id>
  </id_info>
  <brief_title>The CUSA Clarity Soft Tissue Removal Study</brief_title>
  <official_title>Clinical Performance Investigation of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Soft Tissue Removal During Urological and General Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integra LifeSciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the clinical performance and surgeon preferences of the CUSA® Clarity
      Ultrasonic Surgical Aspirator System for soft tissue removal during surgical procedures. This
      will be evaluated through the effectiveness of soft tissue removal per surgeon assessment and
      Incidence of Adverse Device Effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of soft tissue removal per surgeon assessment.</measure>
    <time_frame>During the surgery</time_frame>
    <description>Multifactorial 5-point Likert scale (1 (worst) to 5 (best))</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Benign, Malignant Tumors or Other Soft Tissue Removal</condition>
  <condition>Nephrectomy or Partial Nephrectomy With Parenchyma Removal</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CUSA Clarity Ultrasonic Surgical Aspirator System use</intervention_name>
    <description>Assessment of the CUSA® Clarity Ultrasonic Surgical Aspirator System use during urological or general surgery for soft tissue removal</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient requiring removal of soft tissue with an ultrasonic aspirator during urological or
        general surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 years of age

          -  Subject requires removal of soft tissue with an ultrasonic aspirator during urological
             or general surgery

          -  Subject is an appropriate candidate to receive use of the CUSA® Clarity Ultrasonic
             Surgical Aspirator System product for soft tissue removal during surgery, per the
             study surgeon

          -  Subject signed the IRB/EC-approved informed consent form demonstrating that the
             subject is willing and able to participate in this clinical study and to comply with
             all study procedures, if applicable.

        Exclusion Criteria:

          -  Subject is currently pregnant or plans to become pregnant prior to the study index
             surgery

          -  Subject has any significant medical condition that in the opinion of the investigator
             will interfere with protocol evaluation and participation

          -  Subject's surgical plan includes utilizing CUSA® Clarity Ultrasonic Surgical Aspirator
             System for the removal of uterine fibroids

          -  Subject is a prisoner or member of a different vulnerable population that should not
             be included in the study per the investigator or ethics committee.

          -  Intra-operative exclusion criteria : Surgeon does not utilize the CUSA® Clarity
             Ultrasonic Surgical Aspirator System for soft tissue removal during surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Marzuola</last_name>
    <role>Study Director</role>
    <affiliation>Integra LifeSciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marilyne Blanc</last_name>
    <phone>+33 4 37 47 59 37</phone>
    <email>marilyne.blanc@integralife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Tummon</last_name>
    <phone>+1 6099365490</phone>
    <email>andrew.tummon@integralife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximilian Schmeding</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ISMETT</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore Gruttadauria</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore Agnes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Ardito</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

